source
- Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s PatientsCognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
- Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challengesAcquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…